Patents Assigned to Tarveda Therapeutics, Inc.
-
Patent number: 11241500Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: December 14, 2017Date of Patent: February 8, 2022Assignee: TARVEDA THERAPEUTICS, INC.Inventors: BenoƮt Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Patent number: 11213590Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: October 27, 2017Date of Patent: January 4, 2022Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
-
Patent number: 11160871Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: October 28, 2016Date of Patent: November 2, 2021Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
-
Publication number: 20210169871Abstract: The present invention provides improved formulation with reduced tert-butanol levels and/or manufacturing process for drug compounds that form a solvate with tert-butanol. For example, the drug compound may be SDC-TRAP-0063.Type: ApplicationFiled: April 3, 2019Publication date: June 10, 2021Applicant: Tarveda Therapeutics, Inc.Inventors: Mark T. BILODEAU, Eugene ZHOROV, Rajesh R. SHINDE, Christopher SEARS, Samantha BRADY, Beata SWERYDA-KRAWIEC
-
Patent number: 10624967Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: July 18, 2017Date of Patent: April 21, 2020Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Patent number: 10548881Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: GrantFiled: February 23, 2017Date of Patent: February 4, 2020Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
-
Patent number: 10322191Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: July 18, 2017Date of Patent: June 18, 2019Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20180273948Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an RNAi agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the RNAi agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: September 23, 2016Publication date: September 27, 2018Applicant: Tarveda Therapeutics, Inc.Inventors: Sudhakar Kadiyala, Donna T. Ward
-
Patent number: 9750818Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: December 16, 2016Date of Patent: September 5, 2017Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Patent number: 9480657Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.Type: GrantFiled: March 17, 2014Date of Patent: November 1, 2016Assignee: Tarveda Therapeutics, Inc.Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood